---
title: "Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290454281.md"
description: "In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80."
datetime: "2026-06-22T14:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290454281.md)
  - [en](https://longbridge.com/en/news/290454281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290454281.md)
generator: "portal-rs"
---

# Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80.

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Iovance Biotherapeutics (IOVA) Stock Trades At A Premium As It Climbed 307%](https://longbridge.com/en/news/299153329.md)
- [IOVA: Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook](https://longbridge.com/en/news/298626037.md)
- [Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating](https://longbridge.com/en/news/296875833.md)
- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)
- [Mizuho Securities Keeps Their Buy Rating on Allstate (ALL)](https://longbridge.com/en/news/299161306.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**